Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include:
- – The completion of seven harvests of high THC cannabis
- – Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence
- – The commencement of our MHRA-approved chronic pain feasibility study (LVL Health)
- – The signing of a new R&D collaboration to explore the development of novel pharmaceutical medicines
Today’s announcement can be read in full by visiting our investor section by clicking here.
James Short, our CEO and founder, and Allan Rowley, our interim CFO, will be hosting a live presentation and Q&A session today at 2.30 pm via Investor Meet Company’s online platform. Investors can sign up for free and attend the presentation by clicking here.